Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

被引：0
|
作者：
Wang, Yong [1 ]
Long, Yaqiu [1 ]
机构：
[1] Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
来源：
CHINESE JOURNAL OF ORGANIC CHEMISTRY | 2011年 / 31卷 / 10期
关键词：
tyrosine kinases; inhibitors; cancer; DFG motif; molecular targeted therapy; BCR-ABL; STRUCTURAL BASIS; RATIONAL DESIGN; RECEPTOR; POTENT; CANCER; DOMAIN; DISCOVERY; PROGRESS; AMN107;
D O I：
暂无
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
Protein tyrosine kinases (PTKs) play a pivotal role in the signal transduction pathways, and their deregulation is highly related with the oncology including bladder, breast, colon, and lung cancers. Compounds that inhibit the kinase activity of PTKs are potential chemotherapeutics to treat tumors. With the emergence of the multiple drug resistance of tumor cells against the existing PTK inhibitors, new mechanism PTK inhibitors are designed and developed. This review is focused on the recent advance of the discovery and development of the small molecular PTK inhibitors, categorized according to the mode of action. Furthermore, the synthesis of the typical structures is described.
引用
收藏
页码：1595 / 1606
页数：12
相关论文
共 60 条
  • [1] Allosteric inhibitors of Bcr-abl-dependent cell proliferation
    Adrián, FJ
    Ding, Q
    Sim, TB
    Velentza, A
    Sloan, C
    Liu, Y
    Zhang, GB
    Hur, W
    Ding, S
    Manley, P
    Mestan, J
    Fabbro, D
    Gray, NS
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (02) : 95 - 102
  • [2] Development of inhibitors for protein tyrosine kinases
    Al-Obeidi, FA
    Lam, KS
    [J]. ONCOGENE, 2000, 19 (49) : 5690 - 5701
  • [3] Recent advances in angiogenesis, anti-angiogenesis and vascular targeting
    Bikfalvi, A
    Bicknell, R
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (12) : 576 - 582
  • [4] Recent progress of Src family kinase inhibitors as anticancer agents
    Cao, Xin
    You, Qi-Dong
    Li, Zhi-Yu
    Wang, Xiao-Jian
    Lu, Xiao-Yun
    Liu, Xiao-Rong
    Xu, Dan
    Liu, Bao
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (10) : 1053 - 1063
  • [5] Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion
    Carmi, Caterina
    Cavazzoni, Andrea
    Vezzosi, Stefano
    Bordi, Fabrizio
    Vacondio, Federica
    Silva, Claudia
    Rivara, Silvia
    Lodola, Alessio
    Alfieri, Roberta R.
    La Monica, Silvia
    Galetti, Maricla
    Ardizzoni, Andrea
    Petronini, Pier Giorgio
    Mor, Marco
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (05) : 2038 - 2050
  • [6] Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors
    Dai, YJ
    Guo, Y
    Frey, RR
    Ji, ZQ
    Curtin, ML
    Ahmed, AA
    Albert, DH
    Arnold, L
    Arries, SS
    Barlozzari, T
    Bauch, JL
    Bouska, JJ
    Bousquet, PF
    Cunha, GA
    Glaser, KB
    Guo, J
    Li, JL
    Marcotte, PA
    Marsh, KC
    Moskey, MD
    Pease, LJ
    Stewart, KD
    Stoll, VS
    Tapang, P
    Wishart, N
    Davidsen, SK
    Michaelides, MR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (19) : 6066 - 6083
  • [7] Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors
    Dai, Yujia
    Hartandi, Kresna
    Soni, Niru B.
    Pease, Lori J.
    Reuter, David R.
    Olson, Amanda M.
    Osterling, Donald J.
    Doktor, Stella Z.
    Albert, Daniel H.
    Bouska, Jennifer J.
    Glaser, Keith B.
    Marcotte, Patrick A.
    Stewart, Kent D.
    Davidsen, Steven K.
    Michaelides, Michael R.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) : 386 - 390
  • [8] Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor
    Dai, Yujia
    Hartandi, Kresna
    Ji, Zhiqin
    Ahmed, Asma A.
    Albert, Daniel H.
    Bauch, Joy L.
    Bouska, Jennifer J.
    Bousquet, Peter F.
    Cunha, George A.
    Glaser, Keith B.
    Harris, Christopher M.
    Hickman, Dean
    Guo, Jun
    Li, Junling
    Marcotte, Patrick A.
    Marsh, Kennan C.
    Moskey, Maria D.
    Martin, Ruth L.
    Olson, Amanda M.
    Osterling, Donald J.
    Pease, Lori J.
    Soni, Niru B.
    Stewart, Kent D.
    Stoll, Vincent S.
    Tapang, Paul
    Reuter, David R.
    Davidsen, Steven K.
    Michaelides, Michael R.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (07) : 1584 - 1597
  • [9] Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds
    Dalgarno, D
    Stehle, T
    Narula, S
    Schelling, P
    van Schravendijk, MR
    Adams, S
    Andrade, L
    Keats, J
    Ram, M
    Jin, L
    Grossman, T
    MacNeil, I
    Metcalf, C
    Shakespeare, W
    Wang, Y
    Keenan, T
    Sundaramoorthi, R
    Bohacek, R
    Weigele, M
    Sawyer, T
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2006, 67 (01) : 46 - 57
  • [10] Dan R. R., 2000, ONCOGENE, V19, P5548
123456